ARCHIVES

“Recalcitrant” Cancers? Committee Rewrite Of Pancreatic Bill Raises New Questions

This article is from The Cancer Letter archive.

Vol. 38 No. 34 | September 14, 2012

Download PDF Visit The Full Archive

Related Articles

FDA Committee Okays Carboplatin For Second Line Ovarian Cancer

January 6, 1989

Also Cancer policy board urges NCI to convene panel on long-term care for childhood cancer survivors.

October 10, 2003

AACR President Coffey Urges Clinton to Support Doubling of NIH, NCI Budgets

December 19, 1997

In Brief: Fabien Calvo named chief scientific officer of Cancer Core Europe

December 19, 2014

Abraxane and Gemcitabine Improves Overall Survival

November 30, 2012

Commercial Firms Get Foot In The Door With CREG, But Won’t Be Permitted To Make Money On Grants

January 10, 1975